Dendritic cells for the immunotherapy of cancer

Clinical Oncology

Volumn 14, Issue 3, 2002, Pages 185-192

  Melcher, Alan ^a   Bateman, Andrew ^b   Harrington, Kevin ^b   Ahmed, Atique ^b   Gough, Michael ^b   Vile, Richard ^b  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CANCER VACCINE; EPITOPE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; RECOMBINANT INTERLEUKIN 2; TUMOR ANTIGEN;

ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; BLADDER CANCER; CANCER IMMUNOTHERAPY; CELL CULTURE; CELL MATURATION; CELL TYPE; CELLULAR IMMUNITY; CLINICAL PRACTICE; DENDRITIC CELL; HELPER CELL; HUMAN; IMMUNOLOGY; IMMUNOREACTIVITY; LANGERHANS CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MEDICAL RESEARCH; MOUSE; NONHUMAN; ONCOLOGY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CLASSIFICATION; NEOPLASM;

ANIMALS; ANTIGENS, NEOPLASM; CELLS, CULTURED; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS;

EID: 0036596867     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1053/clon.2001.0038     Document Type: Review

References (33)

1. The immunotherapy and gene therapy of cancer
2. Tumour antigens recognised by T cells
3. Dendritic cells and the control of immunity
4. The role of B7-1/B7-2: CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and downregulation of the immune response
5. Role of bone marrow-derived cells in presenting MHC class 1-restricted tumour antigens
6. Is cancer dangerous to the immune system?
7. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution
8. Origin, maturation and antigen presenting function of dendritic cells
9. Reciprocal control of T helper cell and dendritic cell differentiation
10. Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma
11. Adoptive transfer of immature dendritic cells with autologous or allogeneic tumor cells generates systemic antitumor immunity
12. Natural adjuvants: Endogenous activators of dendritic cells
13. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway
14. Vaccination of melanoma patients with peptide- or tumour lysate-pulsed dendritic cells
15. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
16. Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth
17. Gene-modified dendritic cells for use in tumor vaccines
18. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
19. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12
20. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified
21. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor transfer
22. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma
23. CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells
24. Tumor metastasis biopsy as a surrogate marker of response to melanoma immunotherapy
25. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease
26. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells
27. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
28. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen
29. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration
30. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
31. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer
32. Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer
33. Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer